NCT04305743View on ClinicalTrials.gov

Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A

PHASE4RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 9, 2019

Primary Completion Date

January 1, 2021

Study Completion Date

June 1, 2021

Conditions
Urinary Bladder, OveractiveIncontinence, UrgeIncontinence, UrinaryUrinary Urge IncontinenceUrinary Frequency More Than Once at NightNocturia
Interventions
DRUG

OnabotulinumtoxinA 100 UNT

Intradetrusor onabotulinumtoxin A is administered cystoscopically with 100 unit dose given as either 5 or 20 injections in a single procedure based on the arm the participant is randomized into.

Trial Locations (2)

20010

RECRUITING

MedStar Washington Hospital Center, Washington D.C.

33606

RECRUITING

University of South Florida Health South Tampa Center for Advanced Healthcare, Tampa

Sponsors
All Listed Sponsors
collaborator

Medstar Health Research Institute

OTHER

lead

University of South Florida

OTHER

NCT04305743 - Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A | Biotech Hunter | Biotech Hunter